Alatawi Ahmed D, Hetta Helal F, Ali Mostafa A Sayed, Ramadan Yasmin N, Alaqyli Amirah B, Alansari Wareef K, Aldhaheri Nada H, Bin Selim Talidah A, Merdad Shahad A, Alharbi Maram O, Alatawi Wejdan Alhumaidi Hmdan, Algammal Abdelazeem M
Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia.
Division of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
Diagnostics (Basel). 2025 Sep 5;15(17):2244. doi: 10.3390/diagnostics15172244.
Antibiotic resistance is a growing global health threat, with critical care settings representing one of the most vulnerable arenas due to the high burden of infection and frequent empirical antibiotic use. Rapid and precise diagnosis of infectious pathogens is crucial for initiating appropriate therapy, minimizing unnecessary antimicrobial exposure, and supporting effective stewardship programs. This review explores how innovative diagnostic technologies are reshaping infection management and antimicrobial stewardship in critical care. We examine the clinical utility of molecular assays, multiplex PCR, MALDI-TOF mass spectrometry, metagenomic sequencing, point-of-care (POC) diagnostics, and emerging tools like biosensors and AI-powered predictive models. These platforms enable earlier pathogen identification and resistance profiling, facilitating timely and targeted therapy while minimizing unnecessary broad-spectrum antibiotic use. By integrating diagnostics into stewardship frameworks, clinicians can optimize antimicrobial regimens, improve patient outcomes, and reduce resistance selection pressure. Despite their promise, adoption is challenged by cost, infrastructure, interpretation complexity, and inequitable access, particularly in low-resource settings. Future perspectives emphasize the need for scalable, AI-enhanced, and globally accessible diagnostic solutions. In bridging innovation with clinical application, diagnostic advancements can serve as pivotal tools in the global effort to curb antimicrobial resistance in critical care environments.
抗生素耐药性是一个日益严重的全球健康威胁,由于感染负担重和频繁经验性使用抗生素,重症监护环境是最脆弱的领域之一。快速准确地诊断感染病原体对于启动适当治疗、尽量减少不必要的抗菌药物暴露以及支持有效的管理计划至关重要。本综述探讨了创新诊断技术如何重塑重症监护中的感染管理和抗菌药物管理。我们研究了分子检测、多重聚合酶链反应(PCR)、基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)、宏基因组测序、即时检测(POC)诊断以及生物传感器和人工智能驱动的预测模型等新兴工具的临床效用。这些平台能够更早地识别病原体并进行耐药性分析,有助于及时进行有针对性的治疗,同时尽量减少不必要的广谱抗生素使用。通过将诊断纳入管理框架,临床医生可以优化抗菌治疗方案,改善患者预后,并降低耐药性选择压力。尽管它们前景广阔,但在采用方面面临成本、基础设施、解读复杂性和获取不平等的挑战,尤其是在资源匮乏的环境中。未来的展望强调需要可扩展、人工智能增强且全球可及的诊断解决方案。在将创新与临床应用相结合方面,诊断进展可以成为全球遏制重症监护环境中抗菌药物耐药性努力的关键工具。